• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Inhaled formoterol during one year in asthma: a comparison with salbutamol.

作者信息

Arvidsson P, Larsson S, Löfdahl C G, Melander B, Svedmyr N, Wåhlander L

机构信息

Dept of Pulmonary Medicine, University of Göteborg, Sweden.

出版信息

Eur Respir J. 1991 Nov;4(10):1168-73.

PMID:1687129
Abstract

Eighteen patients, who had previously taken part in a 2 wk cross-over comparison between formoterol and salbutamol, now took part in a one year double-blind study comparing salbutamol 200 micrograms b.i.d. with formoterol 12 micrograms b.i.d. Additional doses were taken when needed and were recorded. Ten patients were started on formoterol and eight on salbutamol. After one month, the patients were allowed to shift to the alternative drug. Two patients withdrew from the study. At the end of the study, 13 of 16 patients were on formoterol, thus showing a long-lasting preference for this drug. Forced expiratory volume in one second (FEV1) dose-response curves for inhaled salbutamol were repeatedly recorded during the study, and no tachyphylaxis was found. One patient stopped taking inhaled steroids but continued taking formoterol and theophylline. He deteriorated with a decreased response to salbutamol. After re-introduction of inhaled steroids his condition improved. This case indicates that effective bronchodilator therapy may mask the deterioration of asthma.

摘要

相似文献

1
Inhaled formoterol during one year in asthma: a comparison with salbutamol.
Eur Respir J. 1991 Nov;4(10):1168-73.
2
A study with cumulative doses of formoterol and salbutamol in children with asthma.
Eur Respir J. 1991 Nov;4(10):1174-7.
3
[Bronchial asthma treated with long-acting beta 2 agonist. Comparison between formoterol (12 mu/g) inhaled twice daily and salbutamol (200 mu/g) inhaled 4 times daily].长效β2受体激动剂治疗支气管哮喘。福莫特罗(12μg)每日吸入两次与沙丁胺醇(200μg)每日吸入四次的比较
Ugeskr Laeger. 1992 Nov 16;154(47):3325-8.
4
Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.福莫特罗常规治疗稳定期哮喘患者后β2肾上腺素能受体调节及支气管扩张剂敏感性
J Allergy Clin Immunol. 1998 Mar;101(3):337-41. doi: 10.1016/S0091-6749(98)70245-3.
5
[The effect of a single dose of formoterol using an aerosol inhaler in asthmatic children. A randomized, controlled, double-blind study].[使用气雾剂吸入器单剂量福莫特罗对哮喘儿童的影响。一项随机、对照、双盲研究]
Rev Mal Respir. 1994;11(1):47-50.
6
Assessment of a relative therapeutic index between inhaled formoterol and salbuterol in asthma patients.哮喘患者吸入福莫特罗与沙丁胺醇相对治疗指数的评估。
Eur J Clin Pharmacol. 2002 Jul;58(4):S61-7.
7
Formoterol, a new long-acting bronchodilator for inhalation.福莫特罗,一种新型长效吸入性支气管扩张剂。
Eur Respir J. 1989 Apr;2(4):325-30.
8
A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma.在稳定期哮喘管理中,每日两次吸入福莫特罗与每日四次吸入沙丁胺醇的三个月比较。
Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):622-5. doi: 10.1164/ajrccm/144.3_Pt_1.622.
9
The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol.高剂量福莫特罗对慢性阻塞性肺疾病的肺部及肺外效应:与沙丁胺醇的比较
Respirology. 2004 Mar;9(1):102-8. doi: 10.1111/j.1440-1843.2003.00525.x.
10
Protective effect of budesonide/formoterol compared with formoterol, salbutamol and placebo on repeated provocations with inhaled AMP in patients with asthma: a randomised, double-blind, cross-over study.布地奈德/福莫特罗与福莫特罗、沙丁胺醇和安慰剂对比在哮喘患者中对吸入 AMP 重复激发的保护作用:一项随机、双盲、交叉研究。
Respir Res. 2010 May 28;11(1):66. doi: 10.1186/1465-9921-11-66.

引用本文的文献

1
Beta-Adrenergic Agonists.β-肾上腺素能激动剂
Pharmaceuticals (Basel). 2010 Mar 30;3(4):1016-1044. doi: 10.3390/ph3041016.
2
Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children.长效β2受体激动剂与相同剂量吸入性糖皮质激素联合应用于成人及儿童慢性哮喘的疗效比较
Cochrane Database Syst Rev. 2010 May 12(5):CD005535. doi: 10.1002/14651858.CD005535.pub2.
3
Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma.
在患有持续性哮喘的成人和儿童中,长效β2受体激动剂与高剂量吸入性类固醇联合使用与单纯使用高剂量吸入性类固醇的比较。
Cochrane Database Syst Rev. 2010 Apr 14(4):CD005533. doi: 10.1002/14651858.CD005533.pub2.
4
Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children.对于未使用过类固醇的成人和儿童持续性哮喘,吸入长效β2受体激动剂联合吸入性类固醇作为一线治疗方案。
Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD005307. doi: 10.1002/14651858.CD005307.pub2.
5
Safety of long-acting beta-agonists: urgent need to clear the air remains.长效β受体激动剂的安全性:仍迫切需要澄清事实。
Eur Respir J. 2009 Jan;33(1):3-5. doi: 10.1183/09031936.00163408.
6
Comparison of the Bronchodilator Effect of Inhaled Short- and Long-Acting beta(2)-Agonists in Children with Bronchial Asthma: A Randomised Trial.吸入性短效和长效β2-激动剂在儿童支气管哮喘中的支气管扩张作用比较:一项随机试验。
Clin Drug Investig. 1998;16(1):19-24. doi: 10.2165/00044011-199816010-00003.
7
Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma.长效β2受体激动剂与茶碱用于哮喘维持治疗的比较
Cochrane Database Syst Rev. 2007 Jul 18;2007(3):CD001281. doi: 10.1002/14651858.CD001281.pub2.
8
Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid.用于成人和儿童慢性哮喘的长效β2受体激动剂,其背景治疗包含不同种类或不包含吸入性糖皮质激素。
Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD001385. doi: 10.1002/14651858.CD001385.pub2.
9
Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial.布地奈德福莫特罗单剂量吸入器治疗成人和青少年中重度哮喘的疗效和安全性:一项随机临床试验
Drugs. 2006;66(17):2235-54. doi: 10.2165/00003495-200666170-00006.
10
A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease.吸入长效β2受体激动剂治疗阻塞性肺疾病的获益-风险评估
Drug Saf. 2004;27(10):689-715. doi: 10.2165/00002018-200427100-00001.